Bulgaria's Sopharma lifts 9-mo non-cons net profit, sales in Ukraine grow 23%

The company's sales revenue added 2% year-on-year to 155.5 million levs in the January-September period, Sopharma said in an interim financial statement.

Sopharma's sales in Bulgaria dropped 8% on the year to 58.1 million levs, while sales in Europe increased by 17% to 84.2 million levs, mainly due to the rise in exports to Ukraine and Russia. The drug maker's sales in other countries decreased by 21% to 13.1 million levs.

The drug maker booked total operating revenue of 176.2 million levs in the review period, up from 169.6 million levs in the comparable period of 2018.

Sopharma's total operating expenses remained relatively unchanged year-on-year at 139.6 million levs.

Sopharma has 10 production facilities with a portfolio of over 200 products.

The company's shares closed Tuesday's trading session on the Bulgarian Stock Exchange unchanged at 3.35 levs.

(1 euro = 1.95583 levs)